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A comparison of the effect of intermittent and
continuous infusion of meropenem on the prevalence of
nausea in pediatric cystic fibrosis patients
Marissa Cushing, Juanita Draime, Bao-Ngoc Ho, Jordan Nicholls, Bethany Sibbitt, Rebecca Widder
Drs. Rebecca Gryka and Denise Simpson
Dayton Children’s Hospital

STATEMENT OF THE PROBLEM
• Background
• Cystic Fibrosis and Treatment
• Cystic Fibrosis (CF) is a genetic disease, leading to changes of membrane
secretions causing obstruction of smaller airways
• CF patients often develop pulmonary infections and require antibiotic
treatment
• Loss of lung function increases the risk of death in CF patients
• Standard treatment involves beta-lactam antibiotics ex. meropenem
• Pharmacokinetics and Pharmacodynamics of Meropenem
• Meropenem is a broad spectrum beta lactam that acts by lysing microbes
through interfering with bacterial cell wall synthesis.
• Safe and effective treatment, however data on pediatric patients is limited
• Effectiveness of meropenem determined by time sensitive dosing and is
effective only when the minimum inhibitory concentration (MIC) is reached
• Meropenem can be administered as a continuous infusion or intermittent
bolus
• Significance of the Problem
• There is a lack of information regarding the use of meropenem in pediatric CF
patients
• There is a lack of supporting information for the use of one treatment regimen
over the other
• Quality of Life – CF patients struggle with malnutrition and treatment with
meropenem compounds the problem due to significant nausea
• Would a different dosing regimen reduce side effects of meropenem treatment?

OBJECTIVES
To test establish clinical protocols for meropenem administration in pediatric CF
patients admitted to Dayton Children’s with the goal of reducing nausea as a side
effect.
To assess reported nausea and its relationship to serum concentration of
meropenem in pediatric CF patients after administration of meropenem in either a
continuous or intermittent IV infusion.

HYPOTHESES
Null Hypotheses:
•Continuous IV administration of
meropenem will have no effect on the
side effects of nausea when compared to
intermittent administration.

Alternative hypotheses:
•Continuous IV administration of
meropenem will reduce the side effects
of nausea when compared to
intermittent administration

•The differences in serum concentrations
between intermittent and continuous IV
administration of meropenem do not
change the number of dosages of antinausea medications ordered in pediatric
CF patients

•The differences in serum concentration
between intermittent and continuous IV
administration of meropenem do change
the number of dosages of anti-nausea
medications ordered in pediatric CF
patients
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PROPOSED METHODS
Study Design
Crossover study designed to compare blood levels of meropenem and effect on
nausea in pediatric cystic fibrosis patients
Sample
This pilot study will comprise approximately 10 subjects from ages seven to
twenty-one
Data Collection and Measurement
Cross over study
• Patients randomly divided into two treatment groups
• One initially receives intermittent dosing of meropenem
• One receives continuous infusion of meropenem
• Then groups will switch after four days
• Continuous dose 120 mg/kg/day
• Intermittent dose 40 mg/kg/dose infused over 30 minutes every 8 hours
Serum Meropenem
• Determined through blood draw
• Intermittent dose: After the third dose
• Continuous dose: After day three
Nausea Scale
• Levels of nausea will be determined by recording frequency of Kytril doses
requested
PICC line
• Sub-study to be conducted to determine reliability of serum levels taken from
PICC line
• Serum levels of meropenem in both groups compared between PICC line
blood draws and peripheral blood draws.
HPLC Assay
• Meropenem concentrations will be measured utilizing a High Pressure Liquid
Chromatography (HPLC) instrument

PROPOSED ANALAYSES

Nausea levels: average the doses of Kytril requested by each patient, number of
episodes of emesis
Two tailed t test (α =0.05, and β = 0.2)
Comparison of the means of two treatment arms.
Concentration of meropenem in blood
Arithmetic mean will be calculated for each sample (95% confidence interval)
Comparison of Treatment Arms
Two-tailed t-test will be used to compare means of the two treatment arms
Two-tailed t-test will be used to compare the two types of blood draw methods

LIMITATIONS

• Small sample size will limit the generalizability of the results.
• Additional medication regimens may contribute to nausea.

FUTURE DIRECTION
The goal of this study is to provide a
framework for further multi-site studies of
the same nature.

TIMELINE
• September 2013: Obtain IRB approval
• September 2013-2014: Enrollment and
sample collection
• September 2013-March 2015: Sample
and Data analysis
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